EC Number   |
Protein Variants |
Reference |
|---|
   3.4.21.27 | FXI/G326C |
mutant of FXI with Gly326 residue mutated to Cys326 |
667620 |
| 3.4.21.27 | G104R |
this mutation in the PK A2 domain associated with CRM+ PK deficiency causes decreased kininogen binding |
707856 |
| 3.4.21.27 | G155E |
is a rare example of a mutation causing CRM+ FXI deficieny |
707856 |
| 3.4.21.27 | G193A |
site-directed mutagenesis, the mutant shows reduced catalytic activity and impaired binding of inhibitors 4-aminobenzamidine and diisopropylfluorophosphate, respectively, indicating distortion of, or altered accessibility to, the S1 and oxyanion-binding sites |
683169 |
| 3.4.21.27 | G193D |
site-directed mutagenesis, the mutant shows reduced catalytic activity and binding of inhibitors 4-aminobenzamidine and diisopropylfluorophosphate impaired 1.6-36fold, respectively, indicating distortion of, or altered accessibility to, the S1 and oxyanion-binding sites |
683169 |
| 3.4.21.27 | G193E |
site-directed mutagenesis, the mutant shows reduced catalytic activity and impaired binding of inhibitors 4-aminobenzamidine and diisopropylfluorophosphate, respectively, indicating distortion of, or altered accessibility to, the S1 and oxyanion-binding sites |
683169 |
| 3.4.21.27 | G193K |
site-directed mutagenesis, the mutant shows reduced catalytic activity and binding of inhibitors 4-aminobenzamidine and diisopropylfluorophosphate impaired 35-478fold, respectively, indicating distortion of, or altered accessibility to, the S1 and oxyanion-binding sites |
683169 |
| 3.4.21.27 | G193R |
site-directed mutagenesis, the mutant shows reduced catalytic activity and impaired binding of inhibitors 4-aminobenzamidine and diisopropylfluorophosphate, respectively, indicating distortion of, or altered accessibility to, the S1 and oxyanion-binding sites |
683169 |
| 3.4.21.27 | G193V |
site-directed mutagenesis, the mutant shows reduced catalytic activity and impaired binding of inhibitors 4-aminobenzamidine and diisopropylfluorophosphate, respectively, indicating distortion of, or altered accessibility to, the S1 and oxyanion-binding sites |
683169 |
| 3.4.21.27 | G400V |
exhibits a dominant negative effect when coexpressed with wild-type FXI and is associated with FXI deficiency that may be inherited in a dominant manner |
707856 |
